Advaxis Inc

Advaxis — Investor Presentation (February 2018)

42 slides from Advaxis's investor presentation, Feb 21, 2018

  1. Slide 1: Focused on Harnessing Lm Technology to Bring New Treatments to Market

    ADVAXKIS Focused on Harnessing Lm Technology™ To Bring New Treatments to Market February 2018

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability and strategies to develop and commercialize cancer immunotherapies, timing of planned clinical trials and regulatory milestones, potential partnershi

  3. Slide 3: Advaxis Immunotherapies

    ADVAXIS IMMUNOTHERAPIES™ A late-stage biotechnology company creating cancer immunotherapies that enlist the body’s own immune system to fight cancer. Advaxis’ proprietary Lm targeted immunotherapy is a new approach toward an effective cancer vaccine. Our Lm Technology has achieved safety and efficac

  4. Slide 4: Advaxis, Inc: Investment Snapshot

    Advaxis, Inc: Investment Snapshot IMMUNOTHERAPIES™ + Platform based on attenuated Lm (Listeria Monocytogenes) + Multiple approaches to impacting the immune system + Manageable safety profile: common AEs are mostly mild to moderate that have been transient and associated with infusion * 3 clinical st

  5. Slide 5: Who is Advaxis? Company Overview

    ADVAXIS IMMUNOTHERAPIES™ Who is Advaxis? Company Overview

  6. Slide 6: Who is Advaxis?

    Who is Advaxis? Creating Next-Generation Cancer Immunotherapies, Using a Proprietary Lm Platform Product Candidate Franchise Overviews HPV- associated cancers nasona. ‘October 2013. Personal a Neoantigen Program oe tan S10 on shared (oo det elect Neoantigens ees ieee EES : (Hotsp Mutations) Multiple

  7. Slide 7: Who is Advaxis? Experience and Expertise are Our Greatest Assets

    Who is Advaxis? Experience and Expertise are Our Greatest Assets Interim Chief Executive Officer @ Ge ettcare MIA Geeen cS BRACCO “Ww Chief Scientific Officer Chief Financial Officer iach es PHARMACIA Qressre AESGEN VP, Technical Operations Sr. VP, Product Development (Weare BN Incyte et Oe ony Ct Q

  8. Slide 8: Our Differentiator: Lm Technology Platform

    ADVAXIS IMMUNOTHERAPIES™ Our Differentiator: Lm Technology Platform.

  9. Slide 9: Lm Technology Features

    9 Lm Technology Features re eae Multiple immunotherapy mechanisms: potent innate immune stimulation via TLRs and PAMPs including the STING receptor, strong CD8* and CD4* T cell responses, epitope spreading, and immune suppression by disabling Tregs and MDSCs in the TME Multifaceted mechanism Unique

  10. Slide 10: Lm Technology: Mechanism of Action

    ADVAXIS Lm Technology: Mechanism of Action 10 APC, antigen-presenting cell; Lm, Listeria monocytogenes; MHC, major histocompatibility complex; TAA, tumor-associated antigen

  11. Slide 11: Harnessing the Immune System with Lm Technology

    Harnessing the Immune System with Lm Technology <= a) The Power of Lm == Proprietary technology: protected by a range of patents and applications, potentially stretching into 2038 Clinically validated: improvement of 12 month survival rates in Ph 2 metastatic cervical cancer studies, warranting conf

  12. Slide 12: Building the Future of Immuno-Oncology

    Building the Future of Immuno-Oncology 5 eels 2017 y Lm 2014 CAR-T Technology Leveraging this 1980s Immune proprietary and unique Checkpoint platform to develop new Cancer Vaccines cancer immunotherapies Inhibitors CAR, chimeric antigen recepto

  13. Slide 13: IMMUNOTHERAPIES™

    IMMUNOTHERAPIES™

  14. Slide 14: Expansion of Lm Technology Beyond HPV: Four Key Franchises

    Expansion of Lm Technology Beyond HPV: Advaxis Focus on Four Key Franchises HPV-Related Cancers The Proof of Concept HOT Expansion into the Most Common Cancer Types NEO Individualized Neoantigens Prostate Cancer

  15. Slide 15: ADXS-HPV: Efficacy Data

    ADXS-HPV: Efficacy Data HPV-associated cancers studied.) GOG-0265: Improvement of survival rates in 3 cervical cancer anal cancer. and recurrent/metastatic cervical cancer 34 s i 12-month and medi: II survival head and neck cancer’ J ‘month and median overall survival Shannan ee improvement vs logis

  16. Slide 16: Expansion of Lm Technology Beyond HPV: Four Key Franchises

    Expansion of Lm Technology Beyond HPV: Advaxis Focus on Four Key Franchises HPV-Related Cancers * Axalimogene filolisbac (AXAL) demonstrated highest 12 mo. OS in metastatic CC as observed by GOG across many trials in that population Planned path to CC commercialization: — Two registrational trials p

  17. Slide 17: The Future of Lm Technology: Clinical Trial Programs

    The Future of Lm Technology Clinical Trial Programs — In Progress and On the Horizon CANCER INDICATION PARTNER | mo PHASE 1 PHASE 2 PHASE 3 AIM2CERV: High-Risk, Locally Advanced Cervical Metastatic Cervical Combination with IMFINZI™ AstraZeneca ADVANCE: Metastatic Cervical Combination with OPDIVO® (

  18. Slide 18: Multiple anticipated inflection points beginning in 2018

    Multiple anticipated inflection points beginning in 201 Metastatic Prostate Ph1/2 Combination with pembrolizumab ADXS-PSA Part A Monotherapy Completed i oli P. tent R it / Metastatic C ie: PRmCC Axalimogene filolisbac Persistent Recurrent Pieiaoualic Cervical Gancer (PRMCC) | Completed Axalimogene f

  19. Slide 19: Business Acceleration: EU Submission for axalimogene filolisbac

    Business Acceleration: EU Submission for axalimogene filolisbac Submitted our Conditional MAA in February 2018

  20. Slide 20: Proof of Concept: HPV-Associated Cancers

    IMMUNOTHERAPIES™ Proof of Concept: HPV-Associated © Cancers

  21. Slide 21: Proof of Concept for Lm Technology

    Proof of Concept for Lm Technology Phase 2 Study in India: Prolonged Survival and Tumor Response in Randomized, Multicenter Phase 2 Study in Recurrent/ Refractory CC Illustrated the Promise of Lm Technology’ ¥ 34.9% 12-month survival rate (38/109), 24.8% (27/109) 18-month survival rate, 3 confirmed

  22. Slide 22: Regulatory Pathway

    Regulatory Pathway Our cervical franchise remains the cornerstone of our Lm Platform — ADVANCE Metastatic Combination Study with axalimogene filolisbac and nivolumab ¢ Metastatic cervical cancer is an area of high unmet need * Combination of axalimogene filolisbac with nivolumab: significant opportu

  23. Slide 23: HPV Franchise: Strategic Harmonization to Axalimogene Filolisbac

    HPV Franchise: Strategic Harmonization to Axalimogene Filolisbac Multiple anticipated benefits e Enhanced global regulatory strategy ¢ Developmental strategic efficiencies gained ¢ Streamlined commercial strategy ¢ Two registrational studies will be ongoing for patients in need GOGINRG Study 0265 CS

  24. Slide 24: IMMUNOTHERAPIES™

    IMMUNOTHERAPIES™

  25. Slide 25: Capitalizing on the Individualized Medicine Market with Lm Technology

    Capitalizing on the Individualized Medicine Market with Lm Technology IMMUNOTHERAPIES™ Ss ADXS-NEO is designed to create truly individualized therapies by activating the patient's immune system to respond against their own unique mutations (neoantigens) within the tumor

  26. Slide 26: NEO to Patients

    NEO to Patients Massive Parallel Sequencing of tumor biopsies Identify neoepitopes Patient-specific Immunotherapies Advaxis designs vector based on neoepitopes and bioengineers Lm Patient’s Hospital or Treating Institution Treat patient with personalized immunotherapy vector programmed to his/her ne

  27. Slide 27: ADXS-NEO Proposed Mechanism of Action

    -NEO Proposed Mechanism of Action Once injected into the patient, ADXS- NEO taken up by antigen-presenting cells Tumor-associated ~ antigens APC presenting antigen to T cell 2. The bacteria secrete tumor-associated ») Aaa antigens into the liquid interior of the a eure) APC =) —) Q 3. The antigens a

  28. Slide 28: Planned Phase 1 Dose-Escalation Study of ADXS-NEO

    Capitalizing on the Individualized Medicine Market with Lm Technology A Planned Phase 1 Dose-Escalation Study of Advaxis (ADXS) NEO Expressing Personalized Tumor Antigens Endpoints Tumor Types: Dose — Primary: Metastatic Microsatellite Stable rom Tolerability/Safety Colon Cancer, / N=9-18 Expansion

  29. Slide 29: Further Expansion into Common Cancer Types: ADXS-HOT

    IMMUNOTHERAPIES™ Further Expansion into Common Cancer Types: ADXS-HOT

  30. Slide 30: ADXS-HOT Program

    ADXS-HOT Program Novel cancer immunotherapies leveraging Leverages proprietary Itiple | ] ith Lm Technology to target eee etrong iP hotspot mutations and proprietary immunogenic cancer antigens in multiple solid tumors Designed for broad patient coverage

  31. Slide 31: Leveraging Lm Technology to Treat Most Common Cancers

    Leveraging Lm Technology to Treat Most Common Cancers The Opportunity for ADXS-HOT What is a “Hotspot” mutation?'2 Growth of “Hotspot” mutations (i.e. somatic mutations) is one of the major mechanisms responsible for oncogenesis Genetic profiling of tumors has produced valuable insights into the “Ho

  32. Slide 32: ADXS-HOT: Targeting Multiple OFAs, CTAs and Hotspots

    ADXS-HOT: Targeting Multiple OFAs, CTAs and Hotspots Designed to Increase Patient Applicability and Clinical Activity <. Hotspot mutations have demonstrated pre-clinical activity in Advaxis’ Lm Technology’ Addition of multiple hotspot peptides and OFA/CTAs maximizes patient coverage Each construct d

  33. Slide 33: IMMUNOTHERAPIES™

    IMMUNOTHERAPIES™

  34. Slide 34: ADXS-PSA Metastatic Prostate Cancer

    ADXS-PSA Metastatic Prostate Cancer Phase 1/2 Combination with KEYTRUDA® (pembrolizumab) - (KEYNOTE-046) Inclusion Criteria: Part B Expansion: Endpoints = Progressive metastatic CRPC aoe MERCK « Safety = <2 prior systemic treatment regimens or <1 prior chemotherapeutic in the metastatic setting = Ef

  35. Slide 35: Immune correlative data

    - Immune correlative data Dv aS Baseline Post-Treatment with ADXS-PSA eee Clinical Activity Immunological Activity e ignificantly higher expression levels of gene profiles indicative of activated T helper cells, mature antigen presenting cells, and y M1 macr were observed i in SD ‘patients but not i

  36. Slide 36: Immune correlative data

    - Immune correlative data Baseline Post-Treatment with ADXS-PSA eee Clinical Activity Immunological Activity e ignificantly higher expression levels of gene profiles indicative of activated T helper cells, mature antigen presenting cells, and y M1 macr were observed i in SD ‘patients but not in NSD

  37. Slide 37: Upcoming Milestones

    ADVAXIS IMMUNOTHERAPIES™ Upcoming Milestones

  38. Slide 38: Multiple anticipated inflection points beginning in 2018

    Multiple anticipated inflection points beginning in 201 Metastatic Prostate Ph1/2 Combination with pembrolizumab ADXS-PSA Part A Monotherapy Completed i oli P. tent R it / Metastatic C ie: PRmCC Axalimogene filolisbac Persistent Recurrent Pieiaoualic Cervical Gancer (PRMCC) | Completed Axalimogene f

  39. Slide 39: Harnessing the Immune System with Lm Technology

    Harnessing the Immune System with Lm Technology IMMUNOTHERAPIES™ Efficacy Primary efficacy endpoints met in proof-of-concept clinical trials in HPV- associated cancer Safety Consistent and manageable safety profile in multiple Clinical trials across several tumor types, with no cumulative toxicity S

  40. Slide 40: Thank You

    ADVAXKIS Thank You

  41. Slide 41: GOG-0265 Treatment-Emergent Adverse Event Summary

    GOG-0265 Treatment-Emergent Adverse Event Summary All treated patients (n=50) experienced 21 AE; safety findings from both stages of the study were consistent AE GRADE 1-4 GRADE 1-2 GRADE 3 GRADE 4 Patients with 21 TRAE, n (%) 47 (94) 30 (60) 15 (30) 2 (4)* Fatigue 26 (52) 26 (52) - - Chills 28 (56)

  42. Slide 42: Axalimogene Filolisbac in High-Risk, Locally Advanced Cervical Cancer

    a2 Axalimogene Filolisbac in High-Risk, Locally Advanced Cervical Cancer AIM2CERV Phase 3 Study as Adjuvant Monothera Eligi = HRLACC = FIGO stage I-Il with positive pelvic nodes FIGO stage Il- “> IVA Any FIGO stage with para- aortic nodes Treatment with Treatment with Cisplatin Axalimogene Filolisba

Advaxis — Investor Presentation (February 2018) on 6ix